ChabioTech Applies for Domestic Phase 1 Clinical Trial of Immune Cell Therapy 'CBT101'
[Asia Economy Reporter Minwoo Lee] Cha Biotech announced on the 27th that it has applied to the Ministry of Food and Drug Safety for a Phase 1 clinical trial in Korea of the immune cell therapy 'CBT101,' which mainly consists of autologous natural killer (NK) cells.
Hot Picks Today
If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Opening a Bank Account in Korea Is Too Difficult..."Over 150,000 Won in Notarization Fees Just for a Child's Account and Debit Card" [Foreigner K-Finance Status]②
- Nomura: "KOSPI Could Reach 11,000 This Year"
- "Better Than the Lottery": Reporting Collusion Could Earn Hundreds of Billions... KFTC Announces Administrative Notice to Abolish Whistleblower Reward Cap
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The company explained, "Through this Phase 1 trial, we plan to evaluate the safety and tolerability of 'CBT101' in patients with solid tumors and determine the maximum dosage and recommended dosage for Phase 2 clinical trials."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
!['WHO Declares International Public Health Emergency' Why the Untreatable 'Variant Ebola' Is More Deadly Than COVID-19 [Reading Science]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052110164072055_1779326201.png)
!["Please Help Us": How Much Do Those Bowing 90 Degrees These Days Actually Earn? [Data Pick]](https://cwcontent.asiae.co.kr/asiaresize/307/2026052010120870131_1779239528.png)
